(Sharecast News) - Aptamer Group reported solid progress on both the technical and commercial fronts on Friday as it held its annual general meeting.
The AIM-traded firm said that since its recapitalisation in August, it had undergone a cost reduction initiative, streamlining production processes to boost capacity, and decreased material requirements from customers.
It also continued to expand and convert its commercial pipeline, with a recent partnership involving a genetic medicines company to advance Optimer development, facilitating targeted delivery of new medicines.
At 1121 GMT, shares in Aptamer Group were down 2.5% at 1.17p.
Reporting by Josh White for Sharecast.com.


(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Thursday.


(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Thursday and not separately reported by Alliance News...


(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately report...


(Alliance News) - Aptamer Group PLC said on Tuesday that it has extended its contract with Unilever PLC for the development of novel Optimer binders f...


(Sharecast News) - Custom antibody alternatives business Aptamer said on Tuesday that it has extended its contract with household goods giant Unilever...


(Alliance News) - Aptamer Group PLC on Monday said its work to test Optimer binders with Unilever PLC continues, while it anticipates a sharp decline ...


(Sharecast News) - Aptamer Group, a developer of novel 'Optimer' binders for the life sciences industry, updated the market on its ongoing partnership...


(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.


(Alliance News) - Aptamer Group PLC on Wednesday said it reached an agreement with AstraZeneca PLC.


(Alliance News) - Aptamer Group PLC shares rose on Monday, after it said it has won two new contracts, worth GBP235,000.